Skip to main content
SHINIL PHARMACEUTICAL CO., LTD. logo

SHINIL PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 012790 ISIN · KR7012790002 KO Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2025-03-14 Audit Report / Informat…
Country KR South Korea
Listing KO 012790

About SHINIL PHARMACEUTICAL CO., LTD.

https://shinilpharma.com/

SHINIL PHARMACEUTICAL CO., LTD. is a drug manufacturing company that develops, produces, and sells a diverse range of pharmaceutical products. The company's portfolio encompasses various therapeutic areas, including vitamins, mineral supplements, anti-inflammatory enzymes, antihistamines, appetite stimulants, and treatments for liver disease. Its product offerings also include topical medications such as gels and medicated plasters. The company serves both domestic and international markets.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Shinil Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, revenue, profit), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcing the completion and submission of the audit report to the regulator, rather than the full annual report (10-K) or a standalone audit report (AR). Given the short length and the nature of the disclosure as a formal notification of filing, it fits the 'Report Publication Announcement' (RPA) category. FY 2024
2025-03-14 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Sinil Pharmaceutical Co., Ltd. covering the fiscal year 2024 (2024.01.01-2024.12.31). In the South Korean regulatory context, the 'Business Report' (사업보고서) is the equivalent of the US 10-K, serving as the comprehensive annual report containing financial statements, business operations, and governance information. It is submitted to the Financial Services Commission and the Korea Exchange. FY 2024
2025-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Shinil Pharmaceutical. It outlines the date, location, agenda items (financial statement approval, auditor appointment, director compensation), and details regarding the proposed auditor. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2025-03-07 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Shinil Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of auditors, and director/auditor compensation limits. While it contains financial data (balance sheets, income statements) as reference material for the meeting, the primary purpose of the document is to provide shareholders with the necessary information and agenda items for the upcoming meeting. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI), which provides shareholders with information to request votes for meetings.
2025-03-07 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Shinil Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2025-03-04 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Shinil Pharmaceutical regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming 48th Annual General Meeting. It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure regarding meeting preparation, it falls under the general regulatory filing category.
2024-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.